Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients

NCT00431041 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00431041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00431041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
VECTOR: A Randomized Double-blind Study to Assess the Safety and Efficacy of Solifenacin (Vesicare®) in Comparison to Oxybutynin for Overactive Bladder Patients
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
December 31, 2006
Completion date
February 29, 2008
Enrollment
132 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

overactive bladder